Detraxi to develop a new solution to reduce global blood shortages
Category: #health  By Nikita Chaurasia  Date: 2019-07-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

Detraxi to develop a new solution to reduce global blood shortages

High income-growth countries like China will be the key recipient of the Detraxi biotechnology.

Detraxi, a biotechnology company, is reportedly planning to develop its proprietary biotechnology solution for a range of global health challenges to save millions of lives worldwide. Detraxi has been working in collaboration with some of the world’s most respected and talented scientists across diagnostics, fluid replacement, regenerative medicine and transplantation for the purpose.

Apparently, the biotechnology developed by Detraxi had previously went through numerous clinical trials and is presently undergoing new pre-clinical studies. High income-growth countries like China will be the key recipient of the Detraxi biotechnology. As population of China grows, the market for this technology will become increasingly significant.

Reportedly, in China, blood demand has been exceeding supply. Currently blood products have been able to satisfy only 50 percent of the entire demand. As per the World Health Organization (WHO), 0.92% of population in China have been donating blood, which falls between 1% to 3% rate.  This much rate of blood donation has been anticipated to be required to meet demand. The annual growth rate demand of clinical blood has been reported to be 10% -15%.

According to reliable sources, blood collection has doubled between 2011 and 2016 to 7000 tons. In 2018, 18.4 million units of blood were assigned throughout China. 15.8 million units were distributed within the same Province from where it was collected. But managing supplies of blood is immensely complex process. Refrigerated blood only stays usable for between 35-42 days.

Apparently, biotechnology is presently going through exponential technological development. It has been improving by a factor of 10 every year in terms of cost-benefit. This enhancement has been driving new biotech solutions which have not been made available before.

Sources cited, the progression of latest biotechnologies needs a very high inclination for risk and lots of patience. Detraxi is supported by Hong Kong and London-based technology billionaire Tej Kohli. Kohli reportedly considers that biotechnologies like Detraxi will offer solutions to some of the greatest public health challenges of the world.

Source credit: https://www.businesswire.com/news/home/20190721005001/en/Biotech-Company-Detraxi-Developing-Solution-Eliminate-Global

https://finance.yahoo.com/news/biotech-company-detraxi-developing-solution-000000870.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Mallinckrodt states positive results of Terlipressin in HRS-1 patients
Mallinckrodt states positive results of Terlipressin in HRS-1 patients
By Nikita Chaurasia

The company announced positive results from its Phase 3 CONFIRM trial of terlipressin in Hepatorenal Syndrome Type 1. The study verified HRS-1 reversal along with other 3 components-renal function enhancement, escaping dialysis, and short-term sur...

Rhodes Group & BCBSNM team up to improve patient outcome in New Mexico
Rhodes Group & BCBSNM team up to improve patient outcome in New Mexico
By Nikita Chaurasia

The collaboration aims to enhance patient outcomes within the New Mexico Centennial Care. BCBSNM is currently holds the accolade of being the foremost performer in Postpartum and Prenatal care. Rhodes Group (Rhodes), a Albuquerque-based TriCore...

London’s health startup Thriva bags £6M in Series A funding round
London’s health startup Thriva bags £6M in Series A funding round
By Nikita Chaurasia

The company will use this funding to build towards its ambitious vision of offering optimal healthcare to potential customers. Thriva, a UK-based health service startup, has reportedly managed to secure £6 million through a Series A funding ro...